

Resource Summary Report

Generated by [dkNET](#) on Aug 4, 2026

Phospho-S6 Ribosomal Protein (Ser235/236) Antibody

RRID:AB_331679

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2211, RRID:AB_331679

Antibody Information

URL: http://antibodyregistry.org/AB_331679

Proper Citation: Cell Signaling Technology Cat# 2211, RRID:AB_331679

Target Antigen: Phospho-S6 Ribosomal Protein (Ser235/236)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation: AB_331680.

Antibody Name: Phospho-S6 Ribosomal Protein (Ser235/236) Antibody

Description: This polyclonal targets Phospho-S6 Ribosomal Protein (Ser235/236)

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_331679

Vendor: Cell Signaling Technology

Catalog Number: 2211

Alternative Catalog Numbers: 2211S, 2211L

Record Creation Time: 20250819T225710+0000

Record Last Update: 20250820T034907+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-S6 Ribosomal Protein (Ser235/236) Antibody.

No alerts have been found for Phospho-S6 Ribosomal Protein (Ser235/236) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 192 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Rosen JC, et al. (2026) Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms. *British journal of cancer*, 134(1), 165.

Kral AJ, et al. (2026) Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. *Molecular cell*, 86(1), 60.

Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. *Cell reports. Medicine*, 6(9), 102317.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell chemical biology*, 32(6), 839.

Imani Farahani N, et al. (2025) High-throughput bioprinting to produce micropatterned neuroepithelial tissues and model TSC2-deficient brain malformations. *Cell reports methods*, 101177.

Middleton G, et al. (2025) A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer. *NPJ precision oncology*, 9(1), 67.

Fedoryshchak RO, et al. (2025) PDZ-directed substrate recruitment is the primary determinant of specific 4E-BP1 dephosphorylation by PP1-Neurabin. *eLife*, 13.

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. *Cell reports. Medicine*, 6(1), 101890.

Rossi M, et al. (2025) Dietary nitrate supplementation mitigates age-related changes at the neuromuscular junction in mice. *The Journal of physiology*.

Mei W, et al. (2025) A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor. *Cell*, 188(2), 371.

Pan T, et al. (2025) Delayed forebrain excitatory and inhibitory neurogenesis in STRADA-related megalencephaly via mTOR hyperactivity. *bioRxiv : the preprint server for biology*.

Koshizuka K, et al. (2025) Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. *Cancer research*, 85(16), 3032.

Park S, et al. (2025) Epigenetic regulation of intracellular branched-chain amino acid homeostasis maintains a normal lifespan. *iScience*, 28(7), 112846.

Petrovic D, et al. (2025) Ergothioneine improves healthspan of aged animals by enhancing cGPDH activity through CSE-dependent persulfidation. *Cell metabolism*, 37(2), 542.

Kjærgaard J, et al. (2025) Insulin- and exercise-induced phosphoproteomics of human skeletal muscle identify REPS1 as a regulator of muscle glucose uptake. *Cell reports. Medicine*, 6(6), 102163.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. *Cancer cell*.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. *Cancer research*, 85(18), 3540.

Mostajo-Radji MA, et al. (2025) Fate plasticity of interneuron specification. *iScience*, 28(4), 112295.

Afshar-Saber W, et al. (2025) Neuronal hyperactivity becomes mTORC1 independent due to transcriptional changes in tuberous sclerosis complex disease models. *Cell reports*, 44(12), 116664.

Torres JA, et al. (2024) β -hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease. *iScience*, 27(9), 110773.